Publicly-traded company Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) had a closing price of $3.53 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $20.00, this means that the stock is underpriced by 82.35%. In the past 52 weeks the company’s stock price has moved within the range of $2.91 to $24.45.
This particular stock’s 5-day moving average is 3.38, its 20-day moving average is 4.24 and its 100-day moving average is 7.62. Salarius Pharmaceuticals Inc. (SLRX) currently has 4.22M shares outstanding, which means that its market capitalization is $14.90M.
The Details: Salarius Pharmaceuticals Inc. (SLRX) Financial Health
We can also see what the current Return on Assets is for the company, which is a percentage that lets us know how well it is utilizing its net assets to turn a profit. The lower the percentage, the worse the company is making use of its assets. At the moment, Salarius Pharmaceuticals Inc. Return on Assets is -83.40%.
What Does Wall Street Say about Company?
When investors are considering buying a new stock, they often want to know the general Wall Street consensus on the company – by checking out the average analyst rating, for instance. At the moment, the average analyst rating for SLRX is Hold. Out of 1 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 1 rated it hold, and 0 rated it a Buy.
Three months ago, on the other hand, the average analyst rating for Salarius Pharmaceuticals Inc. (SLRX) was a Overweight – from a survey of 3 analysts. Of the analysts who provided ratings, 2 rated the company a Hold, 0 rated it a Sell, 0 rated it an overweight, 0 rated it an underweight, and 1 rated it a Buy.
Understanding Profitability at Salarius Pharmaceuticals Inc. (SLRX)
When it comes to net revenue, the average estimate from a total of 1 analysts is 251k – compared to 407k posted in the year-ago period.